ArticleHaematologica2024

CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.

Xin Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.